Page 32 - Confidence Interval News Today

1. In this trial emulation study, molnupiravir and nirmatrelvir-ritonavir reduced all-cause mortality in vaccinated and unvaccinated hospitalized patients with coronavirus disease 2019 (COVID-19). 2. Molnupiravir and nirmatrelvir-ritonavir did not cause any significant reduction in intensive care unit (ICU) admissions or need for ventilatory support. Evidence Rating Level: 1 (Excellent) Study Rundown: Molnupiravir and nirmatrelvir-ritonavir have

1. In this randomized controlled trial, there was no significant difference in mortality between participants who received fever prevention for 36 versus 72 hours after cardiac arrest. 2. There was no significant difference in cognitive assessment or disability between participants who received fever prevention for 36 versus 72 hours at three months. Evidence Rating Level:

Here, Dr Michael Irizarry from Eisai discusses the company's highly anticipated Alzheimer’s drug, lecanemab.

Pfizer (NYSE: PFE) announced today positive results from the Phase 3 TALAPRO-2 study of TALZENNA® (talazoparib), an oral poly ADP-ribose polymerase (PARP) inhibitor, in combination with XTANDI® (enzalutamide), demonstrating a statistically significant and clinically meaningful improvement in radiographic ...

Three-year median follow-up data demonstrate significantly improved disease-free survival, non-urothelial tract recurrence-free survival, distant metastasis-free survival and second progression-free survival with adjuvant Opdivo compared to placeboRandomized patients who received Opdivo after radical surgery remaine...

Data to be featured at ASCO GU 2023 demonstrate continued overall survival, progression-free survival and objective response rate benefits with Opdivo in combination with CABOMETYX compared to sunitinib, regardless of IMDC risk scoreThese three-year data – with a median follow-up of 44 months – from CheckMate -9ER r...

The recent Biden campaign to restrict gas stove in homes is decidely inorganic. What might be behind it?

Written by Chat GPT 3.5, partly in “Comic Hipster Style” with Ralph Losey - Losey to Chat: “Use a comedic hipster writing style to explain my eight steps of electronic document review.”...

BioArctic's partner Eisai submits marketing authorization application for lecanemab as treatment for early Alzheimer's disease in Japan - read this article along with other careers information, tips and advice on BioSpace

STOCKHOLM, Jan. 16, 2023 /PRNewswire/ -- BioArctic AB's (publ) (NASDAQ Stockholm: BIOA B) partner Eisai announced today that Eisai has submitted a marketing authorization application for lecanemab